This is an aggregated industry headline. Read the full story at FierceBiotech →
Bain-backed bone specialist Angitia drops lead spinal fusion candidate
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmaceuticals has pivoted away from its lead asset to structure its pipeline around two earlier-stage drug candidates.
By FierceBiotech
· Jul 1, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induc…
The WeekBriefing
Norwich Pharmaceuticals wins FDA approval for generic baloxavir marboxil, expanding affordable access to one-d…
The WeekBioPharma Dive ↗
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewher…